Literature DB >> 23858831

The complex roles of microRNAs in the metastasis of renal cell carcinoma.

Lei Zhang1, Bin Xul, Shuqiu Chen, Kai Lu, Chunhui Liu, Yiduo Wang, Yuming Zhao, Xiaowen Zhang, Dachuang Liu, Ming Chen.   

Abstract

Renal cell carcinoma (RCC) accounts for approximately 3% of cancers in adults as well as the most common neoplasm of the adult kidney with the highest mortality rate at over 40%. Metastasis is the most significant process affecting the clinical management of RCC patients. It occurs in multiple sequential steps. However, the molecular pathways underlying each step still remain obscure. Recent researches have shown that microRNAs (miRNAs) function as regulators in metastasis of RCC. In this article, we review the role of miRNAs in metastasis of RCC, including: specific miRNA signatures of metastatic RCC, metastasis-associated targets and pathways of miRNAs in RCC, miRNAs participate in epithelial-mesenchymal transition (EMT), miRNA DNA methylation signature in RCC metastasis and so on. MiRNAs are potential to serve as powerful biomarkers of RCC metastasis and novel therapeutic targets in RCC treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23858831     DOI: 10.1166/jnn.2013.6712

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  10 in total

1.  Advanced renal cell carcinoma associated with von Hippel-Lindau disease: A case report and review of the literature.

Authors:  Lei Zhang; Bin Xu; Yiduo Wang; Chunhui Liu; Kai Lu; Yeqing Huang; Ning Liu; Xiaowen Zhang; Shuqiu Chen; Ming Chen
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

Review 2.  Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved.

Authors:  Karthigayan Shanmugasundaram; Karen Block
Journal:  Antioxid Redox Signal       Date:  2016-07-27       Impact factor: 8.401

3.  Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer.

Authors:  Yann Christinat; Wilhelm Krek
Journal:  Oncotarget       Date:  2015-04-30

4.  Detection of dysregulated competing endogenous RNA modules associated with clear cell kidney carcinoma.

Authors:  Hong Wang; Dahua Xu; Huiying Huang; Ying Cui; Chunhua Li; Chunrui Zhang; Shengnan Guo; Lining Zhang; Xiaomu Xu; Jiankai Xu; Jianping Lu; Liqiang Wang; Kongning Li
Journal:  Mol Med Rep       Date:  2018-06-19       Impact factor: 2.952

5.  Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo.

Authors:  Tomoaki Takai; Takuya Tsujino; Yuki Yoshikawa; Teruo Inamoto; Nobuhiko Sugito; Yuki Kuranaga; Kazuki Heishima; Tomoyoshi Soga; Kotaro Hayashi; Kanjiro Miyata; Kazunori Kataoka; Haruhito Azuma; Yukihiro Akao
Journal:  Mol Ther       Date:  2019-03-13       Impact factor: 11.454

6.  MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.

Authors:  Haimin Zhang; Wei Li; Wenyu Gu; Yang Yan; Xudong Yao; Junhua Zheng
Journal:  Cell Prolif       Date:  2019-06-27       Impact factor: 6.831

7.  A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients.

Authors:  Eskezeia Y Dessie; Jeffrey J P Tsai; Jan-Gowth Chang; Ka-Lok Ng
Journal:  BMC Bioinformatics       Date:  2021-05-25       Impact factor: 3.169

8.  MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways.

Authors:  Jianzhou Cui; Yi Yuan; Muthu K Shanmugam; Durkeshwari Anbalagan; Tuan Zea Tan; Gautam Sethi; Alan Prem Kumar; Lina H K Lim
Journal:  Int J Biol Sci       Date:  2021-10-17       Impact factor: 6.580

9.  A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma.

Authors:  Yueping Zhan; Wenna Guo; Ying Zhang; Qiang Wang; Xin-jian Xu; Liucun Zhu
Journal:  Comput Math Methods Med       Date:  2015-10-11       Impact factor: 2.238

10.  Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells by downregulating matrix metalloproteinase-2 and matrix metalloproteinase-9.

Authors:  Shao-Jun Chen; Xu-Dong Yao; B O Peng; Yun-Fei Xu; Guang-Chun Wang; Jianhua Huang; Min Liu; Jun-Hua Zheng
Journal:  Exp Ther Med       Date:  2016-02-08       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.